Subclass mapping was used to compare the expression profiles of the two groups with the dataset of an open melanoma treatment cohort of 47 melanoma patients receiving programmed cell death protein-1 (PD-1) or cytotoxic T lymphocyte-associated protein-4 (CTLA-4) immunosuppression. This evidence concerns the gene CTLA4 and melanoma.